GV20-0251
2025-852
Phase 1 small_molecule active
Quick answer
GV20-0251 for HCC - Hepatocellular Carcinoma is a Phase 1 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- HCC - Hepatocellular Carcinoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active